[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054012":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":51,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin Treatment","EXPERIMENTAL","850mg PO daily",[13],"Drug: Metformin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Metformin","Given PO",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Oliver Eng, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":20},"University of California Irvine Medical",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Chao Family Comprehensive Cancer Center, University of California, Irvine","RECRUITING","Orange","California","92868","United States",{"type":43,"coordinates":44},"Point",[45,46],-117.85311,33.78779,{"lat":46,"lon":45},[49],{"name":23,"role":29,"phone":50,"phoneExt":20,"email":31},"877-827-8839",{"type":25,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Oliver Eng","Associate Professor","100054012",false,"NCT07693452","Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Key Inclusion Criteria (complete details available in protocol):\n\n* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent\u002Frefractory disease s\u002Fp cytoreductive surgery(CRS)\u002Fhyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS\u002FHIPEC\n* Age ≥18 years\n* ECOG performance status ≤2\n\nKey Exclusion Criteria (complete details available in protocol):\n\n* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS\u002FHIPEC\n* Patients currently taking metformin for another medical indication\n* Patients with a prior adverse event to administration of metformin","ALL","18 Years",{"count":63,"type":64},15,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).",[70,71],"Appendiceal Mucinous Neoplasm","Pseudomyxoma Peritonei",[70,71,73,74,75,17],"Pseudomyxoma Peritoneal","PMP","AMNs","2026-07-09",{"date":78,"type":79},"2026-07-13","ACTUAL",{"date":81,"type":79},"2026-06-18",{"date":83,"type":64},"2029-07",{"name":5,"class":6},1]